BCB BANCORP INC Q3 FY2026 earnings call

• Asset Quality Improvement: The bank successfully cleaned up legacy loan quality problems through the sale of over $200 million in criticized/classified loans and write-downs of another $100 million. Non-performing loans (NPLs) dropped to a low $22 million, with the Allowance for Credit Losses (ACL) at $70 million (over 3% of loans).
• Risk Rating Discipline: Management conducted a deep dive into loans over $1 million, resulting in the downgrade of $77 million in previously pass-rated loans to special mention or substandard. This proactive re-risking aimed to surface residual credit risk.
• Cannabis Portfolio Exit: The company continues to forecast the sale of its remaining cannabis portfolio (loans and deposits) in the fourth quarter. These assets were marked to market as of September 30th.
• Capital Raise Success: A successful capital raise was completed to protect the bank’s structure. While dilutive, management views this as necessary to confront legacy problems head-on. The stock price has reacted favorably.
• Operational Restructuring: Expenses were elevated due to professional fees, legal costs, and reincorporation into Delaware. Two larger problem loans were paid in full during the quarter.
• Leadership Changes: The executive ranks were strengthened, and two new directors with extensive public company experience were welcomed.

The provided transcript does not break down financial performance by specific product segments (e.g., Commercial Banking, Retail, etc.). The company reported a Net Interest Margin (NIM) of 303 basis points, which was slightly higher than the estimated range of 290-300 basis points. Deposit costs trended lower, supporting the NIM despite the reversal of approximately $1 million in interest receivable accruals.

• Fourth Quarter Outlook: Management anticipates that a significant portion of the elevated expenses seen in Q3 ($2.5–$3 million) will fall away in Q4, though some elevation is expected due to the ongoing cannabis transaction and balance sheet cleanup.
• DTA Recapture Timing: The $60 million valuation allowance against Deferred Tax Assets (DTA) is binary. If profitability is sustained for five consecutive quarters, the first opportunity to reconsider recapture would be by the end of 2027.
• Future Results: Management expects the fourth quarter results (to be released in late January 2027) to show the 'fruits of labor' from the current diligence process, indicating improved operational health.

• Legacy Credit Risk: Although significantly reduced, the bank still holds criticized and classified loans. There is inherent uncertainty in predicting the behavior of the legacy portfolio, though management believes they have properly accounted for potential losses.
• Expense Volatility: Elevated professional and legal fees are expected to persist in Q4 due to the cannabis sale and corporate restructuring, impacting near-term earnings.
• Deferred Tax Asset Reversibility: The ability to reverse the $60 million DTA valuation allowance is contingent on maintaining consistent profitability over the next several quarters; failure to do so would keep the allowance in place.
• Transaction Execution Risk: The completion of the cannabis portfolio sale remains dependent on finalizing transactions and cleaning up leftover trades/loans held for sale.

Q: Justin Crowley asked about the trajectory of asset quality, specifically how the level of criticized loans might trend into year-end given potential sales activity and reserve comfort. He also inquired about the mechanics and timing of recapturing the Deferred Tax Asset (DTA) valuation allowance if profitability returns, and whether elevated Q3 expenses would normalize in Q4.

A: Management confirmed that asset quality processes have been rigorous, marking nearly $100 million in loans to market and reducing classified loans significantly. They expect further resolution of substandard and NPL issues in Q4. Regarding the DTA, recapture is binary and likely wouldn't occur until the end of 2027, assuming five quarters of supported profitability. On expenses, while Q3 had ~$5M in elevated costs, most should drop in Q4, though some remain tied to the cannabis deal and reincorporation.

Q: Ross Haberman sought clarification on the composition of criticized loans, asking if the figure included cannabis loans, and requested an update on the Business Express loan portfolio's balance, default rate, and reserve coverage. He also asked if any further deterioration occurred since the initial review and if the cannabis sale deal is imminent.

A: Jawad Chaudhry clarified that criticized loans decreased from $207 million in Q2 to $153 million in Q3, noting that performing cannabis loans were marked to market but excluded from this specific criticized count. The Business Express portfolio stands at ~$65 million with improved performance, showing only ~$1 million in quarterly losses and increasing reserve coverage to ~18%. Management expressed high confidence in closing the cannabis sale in Q4, citing no major obstacles.